“Mounjaro® KwikPen™ 7.5 mg is an intermediate dose intended for patients requiring additional glycemic control or enhanced weight-loss effects beyond the 5 mg strength. This dose represents a step-up in therapy while maintaining good tolerability through gradual titration.

At 7.5 mg, tirzepatide provides stronger appetite suppression, improved insulin sensitivity, and better control of post-prandial blood glucose. Patients often experience a more pronounced reduction in caloric intake due to delayed gastric emptying and increased satiety signals.

This strength is particularly useful for patients with moderate insulin resistance or those who have not achieved desired outcomes at lower doses. As with all Mounjaro variants, administration is subcutaneous, once weekly, using the pre-filled KwikPen.”